CJC-1295 Safe

every claim, tied to a source

CJC-1295 references and sources

Every quantitative claim on this site maps to a numbered entry below. Peer-reviewed journals, with DOIs and PubMed links so you can check the original.

Back to the researchRead the FAQ

How to read this list

Every CJC-1295 references entry below is numbered to match the inline citations across the site. The list runs from the early human pharmacokinetic studies that defined the GH/IGF-1 kinetics, through the rat data that established the albumin-conjugate design, to the IGF-1 epidemiology behind the cancer-risk note and the recent GHRH-analog reviews. Where a study reports a number we cite — a half-life, a percentage, a dose — you can trace it to its source here. The full reference list is the backbone of every claim on the research and GH / IGF-1 axis research pages.

  1. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. ↗
  2. Jette L, Leger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. ↗
  3. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797. ↗
  4. Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294. ↗
  5. Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res. 2009;19(6):471-477. ↗
  6. Stanley TL, Feldpausch MN, Oh J, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380-389. ↗
  7. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet. 2004;363(9418):1346-1353. ↗
  8. Henninge J, Pepaj M, Hullstein I, Hemmersbach P. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Test Anal. 2010;2(11-12):647-650. ↗
  9. U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee briefing materials on growth-hormone secretagogues including CJC-1295 (review of 503A bulk drug substances). FDA PCAC, 2024. ↗
  10. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity (GHRH+GHRP co-administration / GH-secretagogue synergy literature). J Clin Endocrinol Metab. 2011. ↗
  11. Granata R, Leone S, Zhang X, Gesmundo I, et al. Growth hormone-releasing hormone and its analogues in health and disease. Nat Rev Endocrinol. 2025;21(3):180-195. ↗
  12. Mechanisms of IGF-1-mediated regulation of skeletal muscle hypertrophy and atrophy. Cells. 2020;9(9):1970. ↗
  13. Growth hormone and growth hormone secretagogue effects on nitrogen balance and urea kinetics. Growth Horm IGF Res. 2009. ↗
  14. Agonistic analogs of growth hormone releasing hormone (GHRH) promote wound healing. Oncotarget. 2016. ↗
  15. GHRH expression plasmid improves osteoporosis and skin damage in aged mice. Growth Horm IGF Res. 2021. ↗